| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
33,580,000 |
| Market
Cap: |
85.96(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.738 - $3.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.5 |
| Insider 6 Months : 12.5 |
| Insider 3/6 Months : 24.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rezolute is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases related to chronic glucose imbalance. Co.'s primary clinical asset, RZ358, is a potential treatment for congenital hyperinsulinism, a pediatric genetic disorder characterized by excessive production of insulin by the pancreas. Co.'s second clinical asset, RZ402, is an oral plasma kallikrein inhibitor being developed as a potential therapy for the chronic treatment of diabetic macular edema.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
188,903 |
188,903 |
193,903 |
3,432,245 |
| Total Buy Value |
$319,782 |
$319,782 |
$329,282 |
$12,634,145 |
| Total People Bought |
4 |
4 |
4 |
5 |
| Total Buy Transactions |
13 |
13 |
14 |
19 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Welch David F |
Director |
– • – |
2017-02-09 |
4 |
B |
$0.97 |
$3,007 |
I/I |
3,100 |
23,100 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-02-08 |
4 |
B |
$0.98 |
$4,900 |
I/I |
5,000 |
20,000 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-02-07 |
4 |
B |
$0.99 |
$4,950 |
I/I |
5,000 |
15,000 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-02-06 |
4 |
B |
$0.96 |
$4,800 |
I/I |
5,000 |
10,000 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-02-03 |
4 |
B |
$0.95 |
$4,750 |
I/I |
5,000 |
5,000 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-01-20 |
4 |
B |
$1.07 |
$10,682 |
I/I |
9,983 |
1,791,415 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-01-19 |
4 |
B |
$0.95 |
$9,500 |
I/I |
10,000 |
1,781,432 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-01-18 |
4 |
B |
$1.00 |
$5,000 |
I/I |
5,000 |
1,771,432 |
2.1 |
- |
|
| Welch David F |
Director |
– • – |
2017-01-12 |
4 |
B |
$0.95 |
$4,750 |
D/D |
5,000 |
15,000 |
2.31 |
- |
|
| Welch David F |
Director |
– • – |
2017-01-11 |
4 |
B |
$0.94 |
$4,693 |
D/D |
5,000 |
10,000 |
2.31 |
- |
|
| Welch David F |
Director |
– • – |
2017-01-10 |
4 |
B |
$0.91 |
$4,571 |
D/D |
5,000 |
5,000 |
2.31 |
- |
|
| Welch David F |
Director |
– • – |
2015-06-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,766,432 |
|
- |
|
| Elam Nevan C |
Chief Executive Officer |
• • – |
2015-02-09 |
4 |
S |
$0.00 |
$0 |
I/I |
(842,949) |
0 |
|
- |
|
| Alpha Venture Capital Partners, L.p. |
10% Owner |
– – • |
2014-04-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,152,847 |
|
- |
|
| Elam Nevan C |
Chief Executive Officer |
• • • |
2014-03-31 |
4 |
A |
$275,000.00 |
$2,147,483,647 |
I/I |
1,057,693 |
5,057,693 |
|
- |
|
| Konus Advisory Group, Inc. |
10% Owner |
– – • |
2014-03-31 |
4 |
A |
$275,000.00 |
$2,147,483,647 |
D/D |
1,057,693 |
5,057,693 |
|
- |
|
| Huh Hoyoung |
Director |
– • • |
2014-03-31 |
4 |
A |
$275,000.00 |
$2,147,483,647 |
I/I |
1,057,693 |
5,057,693 |
|
- |
|
| Elam Nevan C |
Chief Executive OfficerOfficer |
• • • |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,000,000 |
|
- |
|
| Kukekov Nickolay |
Director |
– • – |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,597,074 |
|
- |
|
| Kukekov Nickolay |
Director |
– • – |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,392,000 |
|
- |
|
| Huh Hoyoung |
Director |
– • • |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,000,000 |
|
- |
|
| Mantripragada Sankaram |
Chief Scientific OfficerOffice |
• – • |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,000,000 |
|
- |
|
| Konus Advisory Group, Inc. |
10% Owner |
– – • |
2013-01-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,000,000 |
|
- |
|
| Kaeyo Investments Ltd |
10% Owner |
– – • |
2012-09-04 |
4 |
S |
$0.08 |
$75,075 |
D/D |
(893,750) |
0 |
|
- |
|
| Turnowski Guy |
Secretary |
• • – |
2012-09-04 |
4 |
S |
$0.08 |
$840 |
D/D |
(10,000) |
0 |
|
- |
|
138 Records found
|
|
Page 5 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (3.4%) 
